This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wallock, M. Articles by Walenga, J. M Search for Related Content PubMed PubMed Citation Articles by Wallock, M. Articles by Walenga, J. M Social Bookmarking                   What's this?

Evaluation of a new point of care heparin test for cardiopulmonary bypass: the TAS heparin management test

Departments of Thoracic and Cardiovascular Surgery, Pharmacology, and the Cardiovascular Institute, Loyola University Medical Center, Maywood, Illinois

Walter P Jeske

Departments of Thoracic and Cardiovascular Surgery, Pharmacology, and the Cardiovascular Institute, Loyola University Medical Center, Maywood, Illinois

Mamdouh Bakhos

Departments of Thoracic and Cardiovascular Surgery, Pharmacology, and the Cardiovascular Institute, Loyola University Medical Center, Maywood, Illinois

Jeanine M Walenga

Departments of Thoracic and Cardiovascular Surgery, Pharmacology, and the Cardiovascular Institute, Loyola University Medical Center, Maywood, Illinois, jwaleng{at}lumc.edu

Patients undergoing cardiopulmonary bypass (CPB) require anticoagulation with heparin to avoid thrombosis within the bypass circuit. The common method used to monitor the degree of anticoagulation is the activated clotting time (ACT). We evaluated a novel point of care device, the TAS (Pharmanetics, Raleigh, NC, USA) heparin management test (HMT), for its suitability in monitoring anticoagulation during CPB. In vitro analysis showed a dose-response (r ²=0.988) of the HMT from 0.078-10.0 U/ml heparin, covering the range of heparin used during cardiac surgery (2-5 U/ml). Fifty randomly selected patients undergoing CPB were studied. Preheparin clotting times for these patients were 143±32 s for the HMT and 146±18 s for the ACT; 435±60 s HMT and 438±39 s ACT during CPB; 145±50 s HMT and 128±14 s ACT post-protamine (r ²=0.797). -Aminocaproic acid treatment for inhibition of fibrinolysis did not affect the HMT. We conclude that the HMT correlates well with the ACT and may be useful for monitoring heparin during CPB. Advantages of the HMT are small sample volume and good sensitivity to heparin.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. A Spinler, A. K Wittkowsky, E. A Nutescu, and M. A Smythe Anticoagulation Monitoring Part 2: Unfractionated Heparin and Low-Molecular-Weight Heparin Ann. Pharmacother., July 1, 2005; 39(7): 1275 - 1285. [Abstract] [Full Text] [PDF]

				M. A. Smythe and A. Caffee Anticoagulation Monitoring Journal of Pharmacy Practice, October 1, 2004; 17(5): 317 - 326. [Abstract] [PDF]

				U. Cammerer, W. Dietrich, T. Rampf, S. L. Braun, and J. A. Richter The Predictive Value of Modified Computerized Thromboelastography and Platelet Function Analysis for Postoperative Blood Loss in Routine Cardiac Surgery Anesth. Analg., January 1, 2003; 96(1): 51 - 57. [Abstract] [Full Text] [PDF]